Tags: Cancer | lung | cancer | drug | azd9291

New Lung Cancer Drug Shows Blockbuster Potential

Friday, 17 April 2015 08:27 AM

An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild its sales following patent losses on older drugs.

An analysis presented at the European Lung Cancer Conference in Geneva demonstrated a median progression-free survival for patients on the drug of 13.5 months.

AZD9291, like a rival product in development at Clovis Oncology, targets a genetic mutation that helps tumors evade current lung cancer pills, including AstraZeneca's own established product Iressa.

AstraZeneca has said it believed AZD9291 could sell as much as $3 billion a year.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday. AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number...
lung, cancer, drug, azd9291
130
2015-27-17
Friday, 17 April 2015 08:27 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved